Medtronic Raises 2027 Forecasts Amid Heart Device Surge

Medtronic has revised its fiscal 2027 financial forecasts upward, citing robust demand for its heart devices used in complex cardiovascular procedures. The medical technology giant now anticipates annual organic revenue growth between 7.25% and 7.75%, an increase from the previous range of 6.75% to 7.25%. The lower end of its adjusted per-share profit forecast has also been raised to $5.94 from $5.90, while the upper end remains at $6.

CEO Geoff Martha attributed the positive outlook to the strength across Medtronic's various business segments and the growing impact of newer growth platforms. "What gives us confidence is not simply the strength of the quarter, but importantly, the breadth of performance across our businesses and the increasing contributions from newer growth platforms," Martha stated during a post-earnings call.

Strategic Investments in Pi-Cardia and Cornerstone Robotics

In addition to its forecast adjustments, Medtronic announced a strategic investment of $80 million in Pi-Cardia, a company specializing in heart-valve repair devices. Medtronic also holds an option to purchase Pi-Cardia for $210 million. Furthermore, the company has invested $700 million in Cornerstone Robotics, securing rights to distribute a robotic surgical device in select markets outside the United States.

Martha emphasized the significance of these investments, particularly in emerging markets where the penetration of soft tissue robotic surgery remains under 1%. He highlighted that Cornerstone's Sentire device complements Medtronic's existing Hugo robotic system.

Strong Cardiovascular Segment Performance

Medtronic's cardiovascular segment reported a 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was largely driven by an 88% surge in its pulsed field ablation portfolio, which is utilized to treat irregular heart rhythms.

The company posted an adjusted quarterly per-share profit of $1.45 on revenue of $9.76 billion, surpassing analysts' expectations of $1.39 per share on $9.55 billion in revenue, according to data compiled by LSEG.

Finance chief Thierry Pieton noted that Medtronic received tariff refunds that nearly offset the duties paid during the quarter. However, future refunds have not been included in the company's outlook.

As Medtronic continues to prioritize high-growth segments within the medtech industry, Martha expressed confidence in targeting large patient pools and significant market segments. "We've had a steady cadence of M&A, and we're prioritizing the higher growth segments of medtech that we have confidence are going to be big segments," Martha said.